Prostacyclin for pulmonary arterial hypertension

BACKGROUND: Pulmonary arterial hypertension (PAH) is characterised by pulmonary vascular changes, leads to elevated pulmonary artery pressures, dyspnoea, a reduction in exercise tolerance, right heart failure, and ultimately death. Prostacyclin analogue drugs mimic endogenous prostacyclin which lead...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cochrane Database Syst Rev
Prif Awduron: Barnes, Hayley, Yeoh, Hui‐Ling, Fothergill, Toby, Burns, Andrew, Humbert, Marc, Williams, Trevor
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Ltd 2019
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492481/
https://ncbi.nlm.nih.gov/pubmed/31042010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012785.pub2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg